BEYAZIT, F. Et Al. 2020. Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content. MEDICAL HYPOTHESES , vol.143 .

BEYAZIT, F., BEYAZIT, Y., Tanoglu, A., & HAZNEDAROĞLU, İ. C., (2020). Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content. MEDICAL HYPOTHESES , vol.143.

BEYAZIT, FATMA Et Al. "Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content," MEDICAL HYPOTHESES , vol.143, 2020

BEYAZIT, FATMA Et Al. "Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content." MEDICAL HYPOTHESES , vol.143, 2020

BEYAZIT, F. Et Al. (2020) . "Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content." MEDICAL HYPOTHESES , vol.143.

@article{article, author={FATMA BEYAZIT Et Al. }, title={Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content}, journal={MEDICAL HYPOTHESES}, year=2020}